Search Within

Michael Morris

  1. "Matthew Milowsky"
Formats
  1. Journal Article (3)
  2. Meeting Abstract (3)
Groups
  1. Department of Medicine (6)
  2. Genitourinary Oncology Service (6)
  3. Solid Tumor Oncology Division (6)
  4. GSK Faculty (2)
  5. Molecular Imaging and Therapy Service (2)
  6. Molecular Pharmacology and Chemistry Program Faculty (2)

More Groups

People
  1. Matthew Milowsky (6)
  2. Howard Scher (4)
  3. Neil Bander (4)
  4. Neeta Pandit-Taskar (2)
  5. Angel Cronin (1)
  6. Chaitanya Divgi (1)

More People

Years
  1. 2016 (1)
  2. 2013 (1)
  3. 2012 (1)
  4. 2008 (1)
  5. 2007 (1)
  6. 2006 (1)
Publications
  1. Journal of Clinical Oncology (3)
  2. BJU International (1)
  3. Clinical Cancer Research (1)
  4. Urologic Oncology: Seminars and Original Investigations (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. American Association for Cancer Research (1)
  3. Elsevier Inc. (1)
  4. Wiley Blackwell (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer
    Journal Article

    Milowsky, M. I.; Galsky, M. D.; Morris, M. J.; Crona, D. J.; George, D. J.; Dreicer, R.; Tse, K.; Petruck, J.; Webb, I. J.; Bander, N. H.; more...
    Urologic Oncology: Seminars and Original Investigations (2016)

    Fulltext@MSK | Save
  • Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer
    Journal Article

    Tagawa, S. T.; Milowsky, M. I.; Morris, M.; Vallabhajosula, S.; Christos, P.; Akhtar, N. H.; Osborne, J.; Goldsmith, S. J.; Larson, S.; Taskar, N. P.; more...
    Clinical Cancer Research (2013)

    Fulltext@MSK | Save
  • Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer
    Journal Article

    Gallagher, D. J.; Cronin, A. M.; Milowsky, M. I.; Morris, M. J.; Bhatia, J.; Scardino, P. T.; Eastham, J. A.; Offit, K.; Robson, M. E.
    BJU International (2012)

    Fulltext@MSK | Save
  • Phase II trial of 177 Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC)
    Meeting Abstract

    Tagawa, S. T.; Milowsky, M. I.; Morris, M. J.; Vallabhajosula, S.; Goldsmith, S.; Matulich, D.; Kaplan, J.; Berger, F.; Scher, H. I.; Bander, N. H.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC)
    Meeting Abstract

    Bander, N. H.; Nanus, D. M.; Milowsky, M. I.; Morris, M. J.; Jeske, S.; Vallabhajosula, S.; Goldsmith, S. J.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase 2 trial of (177)Lutetium (Lu-177) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (Lu-177-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC)
    Meeting Abstract

    Morris, M. J.; Milowsky, M. I.; Pandit-Taskar, N.; Divgi, C.; David, K. A.; Rozario, C. P.; Vallabhajosula, S.; Goldsmith, S. J.; Scher, H. I.; Nanus, D. M.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save